OBJECTIVE: This study examined the dose-dependent effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on heart rate variability (HRV) at rest and during standard laboratory stress tasks. We also investigated whether EPA + DHA supplementation was associated with changes in mood state. METHODS: This placebo-controlled, double-blind, randomized, three-period crossover trial (8-week treatment, 6-week washout) compared two doses of EPA + DHA supplementation (0.85 and 3.4 g/d) in 26 adults with elevated triglycerides. After each treatment period, HRV was assessed during an acute stress protocol that included a resting baseline, standard laboratory stress tasks (speech task and cold pressor), and recovery periods. In addition, mood state was assessed. RESULTS: Root mean square of successive differences in interbeat interval and total power increased 9.9% and 20.6%, respectively, after the high dose relative to placebo (Tukey p = .016 and .012, respectively). The low dose was not significantly different from the high dose or placebo dose. There was a trend for a treatment effect on high-frequency HRV (p = .058), with 21.0% greater power observed after the high dose compared with placebo (Tukey p = .052). Mood did not differ between treatments, and there was no association between mood state and HRV. CONCLUSIONS: In healthy adults with elevated triglycerides, supplementation of 3.4 g/dEPA + DHA resulted in greater HRV, whereas 0.85 g/d EPA + DHA had no effect. These results indicate that EPA + DHA supplementation may improve autonomic tone in adults at increased risk for cardiovascular disease within 8 weeks. TRIAL REGISTRATION: NCT00504309 (ClinicalTrials.gov).
RCT Entities:
OBJECTIVE: This study examined the dose-dependent effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on heart rate variability (HRV) at rest and during standard laboratory stress tasks. We also investigated whether EPA + DHA supplementation was associated with changes in mood state. METHODS: This placebo-controlled, double-blind, randomized, three-period crossover trial (8-week treatment, 6-week washout) compared two doses of EPA + DHA supplementation (0.85 and 3.4 g/d) in 26 adults with elevated triglycerides. After each treatment period, HRV was assessed during an acute stress protocol that included a resting baseline, standard laboratory stress tasks (speech task and cold pressor), and recovery periods. In addition, mood state was assessed. RESULTS: Root mean square of successive differences in interbeat interval and total power increased 9.9% and 20.6%, respectively, after the high dose relative to placebo (Tukey p = .016 and .012, respectively). The low dose was not significantly different from the high dose or placebo dose. There was a trend for a treatment effect on high-frequency HRV (p = .058), with 21.0% greater power observed after the high dose compared with placebo (Tukey p = .052). Mood did not differ between treatments, and there was no association between mood state and HRV. CONCLUSIONS: In healthy adults with elevated triglycerides, supplementation of 3.4 g/d EPA + DHA resulted in greater HRV, whereas 0.85 g/d EPA + DHA had no effect. These results indicate that EPA + DHA supplementation may improve autonomic tone in adults at increased risk for cardiovascular disease within 8 weeks. TRIAL REGISTRATION: NCT00504309 (ClinicalTrials.gov).
Authors: Sheila G West; Sarah K Gebauer; Colin D Kay; Deborah M Bagshaw; David M Savastano; Christopher Diefenbach; Penny M Kris-Etherton Journal: Hypertension Date: 2012-06-04 Impact factor: 10.190
Authors: Sheila G West; Andrea Likos Krick; Laura Cousino Klein; Guixiang Zhao; Todd F Wojtowicz; Matthew McGuiness; Deborah M Bagshaw; Paul Wagner; Rachel M Ceballos; Bruce J Holub; Penny M Kris-Etherton Journal: J Am Coll Nutr Date: 2010-12 Impact factor: 3.169
Authors: Katherine A Sauder; Elyse R Johnston; Ann C Skulas-Ray; Tavis S Campbell; Sheila G West Journal: Psychophysiology Date: 2012-01-03 Impact factor: 4.016
Authors: Ann C Skulas-Ray; Penny M Kris-Etherton; William S Harris; John P Vanden Heuvel; Paul R Wagner; Sheila G West Journal: Am J Clin Nutr Date: 2010-12-15 Impact factor: 7.045
Authors: J H Christensen; M Svensson; C Strandhave; T Madsen; E B Schmidt Journal: Cell Mol Biol (Noisy-le-grand) Date: 2010-02-25 Impact factor: 1.770
Authors: Robert M Carney; Kenneth E Freedland; Phyllis K Stein; Brian C Steinmeyer; William S Harris; Eugene H Rubin; Ronald J Krone; Michael W Rich Journal: Psychosom Med Date: 2010-08-17 Impact factor: 4.312
Authors: Andrew H Kemp; Daniel S Quintana; Marcus A Gray; Kim L Felmingham; Kerri Brown; Justine M Gatt Journal: Biol Psychiatry Date: 2010-02-06 Impact factor: 13.382
Authors: Yongyue Wei; Zhaoxi Wang; Chiung-yu Chang; Tianteng Fan; Li Su; Feng Chen; David C Christiani Journal: PLoS One Date: 2013-10-15 Impact factor: 3.240